This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Sponsored by Omeros Corporation

About this trial

Last updated 11 years ago

Study ID

C09-001

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 14 years ago

What is this trial about?

The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated pupil during surgery and reducing post-operative symptoms of discomfort (such as eye pain and irritation).

What are the participation requirements?

Yes

Inclusion Criteria

- Competent and willing to voluntarily provide informed consent

- 18 years of age or older

- In good general health needing to undergo cataract extraction with lens replacement surgery in one eye, under topical anesthesia

- Other inclusion criteria to be evaluated by the investigator

No

Exclusion Criteria

- No allergies to the medications and/or the active ingredients of any of the study medications

- No medications with the same activities as the of the active ingredients in OMS302 for defined time intervals prior to and after surgery

- No other significant eye injuries, eye conditions or general medical conditions likely to interfere with the evaluation of the study medication

- Other exclusion criteria to be evaluated by the investigator

Locations

Location

Status